Sofosbuvir plus ribavirin with or without peginterferon for the treatment of HCV: Results from a phase 3b study in China
Journal of Gastroenterology and Hepatology Feb 04, 2018
Wei L, et al. - The efficacy and safety of sofosbuvir+ribavirin±peginterferon were evaluated in Chinese patients infected with HCV genotypes 1, 2, 3, or 6. As per the outcomes, in these Chinese patients, sofosbuvir-based regimens were highly effective and safe. Thus, findings suggested that sofosbuvir could serve as the backbone for HCV treatment in China irrespective of genotype.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
